SinuNase Effective For Severe, Chronic Sinusitis After All
This article was originally published in The Pink Sheet Daily
Results make a compelling argument to partnering candidates, Accentia tells “The Pink Sheet” DAILY.
You may also be interested in...
Firm seeks “accelerated or conditional” approval path from FDA.
Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.